Business Context and Reporting Period
Company: Spruce Biosciences, Inc. (SPRB)
Filing Type: Form 8-K (Current Report)
Date of Report: May 13, 2024
Reporting Period: First Quarter ended March 31, 2024
Context: The filing announces the release of financial results for Q1 2024 and provides corporate updates via a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text serves as a cover sheet and does not contain specific numerical data. The filing states that the full text of the press release containing financial results is incorporated by reference as Exhibit 99.1. Consequently, the following metrics are not available in the source text:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt and Liquidity
Note: The filing text does not provide a clear value for any specific financial metric.
Material Changes
The filing text does not detail specific material changes versus the prior comparable period. It only indicates that such information is contained within the press release (Exhibit 99.1) referenced in Item 2.02.
Guidance, Outlook, and Risks
The filing references "corporate updates" provided in the press release but does not explicitly list guidance, outlook, management commentary, risks, contingencies, or unusual items within the body of this 8-K document. Investors must refer to Exhibit 99.1 for these details.
Important Facts for Investor Verification
- Verify the specific Q1 2024 financial results (revenue, net loss, cash position) in the press release attached as Exhibit 99.1.
- Review the "corporate updates" mentioned in Item 2.02 for operational milestones or strategic shifts.
- Confirm the company's status as an "Emerging Growth Company" (indicated as checked in the filing).
- Note that the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, limiting liability for forward-looking statements.